DEVONIAN HEALTH GROUP INC.

Botanical pharmaceutical corporation
  • HOME
  • OUR COMPANY
  • TECHNOLOGY
  • PRODUCTS
    • Therapeutics
    • Purgenesis CosmeceuticalsTM
  • PIPELINE
  • INVESTOR CENTER
  • CAREERS
  • CONTACT
  • FR
Home

Press Releases

2021
  • Press Releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Corporate presentation
  • Financial Reports
  • Analysts
  • Investor and Stock Information
  • Media
  • Corporate Governance
  • What’s New

Subscribe!

Check your inbox or spam folder to confirm your subscription.

Inscrivez-vous!

Vérifiez votre email pour confirmer votre inscription. Si vous ne trouvez pas notre courriel, veuillez vérifier dans vos spams.

Press Releases

April 14, 2021 DEVONIAN HEALTH GROUP INC. RETAINS RENMARK FINANCIAL COMMUNICATIONS INC. TO PROVIDE INVESTOR RELATIONS SERVICES

March 30, 2021 Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering use of Thykamine™ for the treatment of Cardiovascular Diseases

March 25, 2021 Devonian Health Group provides more details on Previously Announced Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Population with Mild-to-Moderate Atopic Dermatitis and the Grant of Stock Options

March 05, 2021 DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS

February 18, 2021 Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis

January 28, 2021 Devonian Health Group Announces voting results of the Annual General and Special Meeting

January 22, 2021 DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO A DEBENTURE HOLDER

DEVONIAN HEALTH GROUP INC.
Farm to Pharm ®
  • TERMS OF USE
  • PRIVACY POLICY
© 2020 Devonian Health Group Inc.
/**/